[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631997":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":30,"centralContacts":37,"locations":43,"responsibleParty":60,"collaborators":30,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":30,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":30,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":30,"overallStatus":82,"whyStopped":30,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Wecare Probiotics Co., Ltd.","INDUSTRY",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Probiotic group","EXPERIMENTAL","Participants in this group will receive Bifidobacterium animalis subsp. lactis BLa36 at a dose of 3 g per sachet, administered once daily for 8 weeks.",[13],"Dietary Supplement: Probiotic",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group","PLACEBO_COMPARATOR","Participants in this group will receive a placebo containing maltodextrin (3 g per sachet), administered once daily for 8 weeks, matched in appearance and administration to the active product.",[19],"Dietary Supplement: Maltodextrin",{"label":21,"type":10,"description":11,"interventionNames":22},"High-activity probiotic group",[23],"Dietary Supplement: High-activity probiotic group",[25,31,35],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DIETARY_SUPPLEMENT","Probiotic","BLa36 will be administered orally once daily for 8 weeks. Follow-up assessments will be conducted at Week 0, Week 4, and Week 8.",[9],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"Maltodextrin","Maltodextrin will be administered orally once daily for 8 weeks. Follow-up assessments will be conducted at Week 0, Week 4, and Week 8.",[15],{"type":26,"name":21,"description":28,"armGroupLabels":36,"otherNames":30},[21],[38],{"name":39,"role":40,"phone":41,"phoneExt":30,"email":42},"Ying Jin","CONTACT","18336086291","1959643812@qq.com",[44],{"facility":45,"status":30,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Suzhou Ninth People's Hospital","Suzhou","Jiangsu","215000","China","CN",{"type":52,"coordinates":53},"Point",[54,55],120.59538,31.30408,{"lat":55,"lon":54},[58],{"name":59,"role":40,"phone":41,"phoneExt":30,"email":42},"Ying Jin, Doctor",{"type":61,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100631997","probiotics-for-constipation-relief-in-adults-100631997",false,"NCT07507955","Probiotics for Constipation Relief in Adults","To Evaluate the Efficacy and Safety of Probiotics in Alleviating Constipation in Adults Through a Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Adults aged 18-65 years;\n2. Individuals diagnosed with constipation, defined as fewer than 3 bowel movements per week and\u002For Bristol Stool Form Scale (BSFS) types 1-2;\n3. Able and willing to comply with all study procedures and complete the study;\n4. Provided written informed consent prior to participation;\n5. Participants (including males) must have no intention of conception from 14 days before screening until 6 months after study completion and agree to use effective contraception.\n\nExclusion Criteria:\n\n1. Recent use of products with similar effects that may interfere with study outcomes; Significant dietary changes during the study period;\n2. History of severe allergy or immunodeficiency;\n3. Pregnant or breastfeeding women, or those planning pregnancy;\n4. Presence of serious systemic diseases (e.g., cardiovascular, pulmonary, hepatic, renal, endocrine, or malignant conditions);\n5. Use of antibiotics within the past 2 weeks;\n6. Individuals with severe psychiatric or neurological disorders;\n7. Poor compliance, including failure to take the study product or attend scheduled visits;\n8. Any other condition deemed unsuitable by the investigator.",true,"ALL","18 Years","65 Years",{"count":74,"type":75},105,"ESTIMATED","INTERVENTIONAL",[78],"NA","This study aims to evaluate the efficacy and safety of Bifidobacterium animalis subsp. lactis BLa36 in adults with functional constipation. In this randomized, double-blind, placebo-controlled trial, participants will receive BLa36 supplementation or placebo for 8 weeks. Clinical outcomes will be assessed using validated gastrointestinal symptom scales, stool characteristics, and quality-of-life measures. In addition, changes in inflammatory and immune markers, gut microbiota composition, metabolic indicators, and gut-brain axis-related parameters will be evaluated to comprehensively determine the effects of BLa36 on intestinal function and overall health.",[81],"Functional Constipation","NOT_YET_RECRUITING","2026-06-05",{"date":85,"type":86},"2026-06-09","ACTUAL",{"date":88,"type":75},"2026-06-10",{"date":90,"type":75},"2027-01-20",{"name":5,"class":6},1]